Nektar Therapeutics (NKTR)
(Delayed Data from NSDQ)
$1.17 USD
-0.03 (-2.50%)
Updated Aug 5, 2024 03:59 PM ET
After-Market: $1.17 0.00 (0.00%) 6:52 PM ET
3-Hold of 5 3
D Value F Growth C Momentum F VGM
Brokerage Reports
Nektar Therapeutics [NKTR]
Reports for Purchase
Showing records 1 - 20 ( 397 total )
Company: Nektar Therapeutics
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: Nektar Therapeutics
Industry: Medical - Drugs
Company: Nektar Therapeutics
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: Nektar Therapeutics
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: Nektar Therapeutics
Industry: Medical - Drugs
Company: Nektar Therapeutics
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: Nektar Therapeutics
Industry: Medical - Drugs
Company: Nektar Therapeutics
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: Nektar Therapeutics
Industry: Medical - Drugs
Company: Nektar Therapeutics
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: Nektar Therapeutics
Industry: Medical - Drugs
Company: Nektar Therapeutics
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: Nektar Therapeutics
Industry: Medical - Drugs
Company: Nektar Therapeutics
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: Nektar Therapeutics
Industry: Medical - Drugs
Company: Nektar Therapeutics
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: Nektar Therapeutics
Industry: Medical - Drugs
Company: Nektar Therapeutics
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: Nektar Therapeutics
Industry: Medical - Drugs
Company: Nektar Therapeutics
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department